Comparative Effectiveness Of Ramipril Versus Losartan In Adults With Primary Hypertension: A Scoping Review

Putu Ngurah Pradnya Wibawa; Ni  Putu Lia Juliantini; Ni  Luh Putu Serly Ekayanti

doi:10.58344/ihj.v5i1.831

Authors

Putu Ngurah Pradnya Wibawa UPTD Dawan II Community Health Center, Indonesia
Ni Putu Lia Juliantini UPTD Dawan II Community Health Center, Indonesia
Ni Luh Putu Serly Ekayanti UPTD Dawan II Community Health Center, Indonesia

DOI:

https://doi.org/10.58344/ihj.v5i1.831

Keywords:

Hypertension, Adult, Losartan, Ramipril, Sistolic blood pressure, Diastolic blood pressure

Abstract

Hypertension remains one of the leading global risk factors for cardiovascular morbidity and mortality. Despite the availability of multiple antihypertensive drug classes, achieving optimal blood pressure control continues to be a major clinical challenge worldwide. This research aims to compare the efficacy of Ramipril and Losartan in the management of Primary Hypertension. This scoping review analyzed articles published between January 2006 and January 2026 from PubMed, ScienceDirect, OpenAlex, and DOAJ. Inclusion criteria included English-language observational studies addressing the efficacy of both antihypertensives. Four articles were selected after a rigorous screening process. Ramipril was more effective in reducing SBP and DBP, whereas Losartan was superior for EF and LV remodeling. Ramipril also increased GSH and total antioxidant status, while Losartan was more effective for metabolic and vascular remodeling biomarkers. Ramipril is commonly associated with adverse effects such as cough, whereas dizziness is more frequently reported with Losartan. Losartan has been shown to be more effective in hypertensive patients with left ventricular hypertrophy (LVH) and may also contribute to improvements in insulin resistance. Further head-to-head comparison studies are needed to guide optimal therapy.

References

Alcocer, L. A., Bryce, A., Brasil, D. D. P., Lara, J., Cortes, J. M., Quesada, D., & Rodriguez, P. (2023). The pivotal role of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in hypertension management and cardiovascular and renal protection: A critical appraisal and comparison of international guidelines. American Journal of Cardiovascular Drugs.

Aqilla, R. S. (2025). Pemberian diet DM RG pada pasien dengan radiculopathy, diabetes mellitus, essential hypertension, spondylosis, spinal stenosis. Jurnal Ilmu Kesehatan.

Bruyn, E., Nguyen, L., Schutte, A., Murphy, A., Perel, P., & Webster, R. (2022). Implementing single-pill combination therapy for hypertension: A scoping review of key health system requirements in 30 low- and middle-income countries. Global Heart.

Brunström, M., & Carlberg, B. (2018). Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: A systematic review and meta-analysis. JAMA Internal Medicine, 178(1), 28–36.

Burnier, M., & Egan, B. M. (2019). Adherence in hypertension. Circulation Research, 124(7), 1124–1140.

Campbell, K. N., Pennese, N., Zaffalon, A., Magalhaes, B., Faiella, M., Caster, D. J., Radhakrishnan, J., Tesar, V., & Trachtman, H. (2022). Efficacy and safety of ACE inhibitor and angiotensin receptor blocker therapies in primary focal segmental glomerulosclerosis treatment: A systematic review and meta-analysis. Kidney Medicine, 4(5), 100457.

Chen, R., Suchard, M. A., Krumholz, H. M., Schuemie, M. J., Shea, S., Duke, J., Pratt, N., Reich, C. G., Madigan, D., & You, S. C. (2021). Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: A multinational cohort study. Hypertension, 78(3), 591–603.

de Boer, I. H., Khunti, K., Sadusky, T., & Tuttle, K. R. (2022). Clinical practice guidelines to synthesize data and provide expert direction on diagnosis and treatment. Guidelines must be evidence-based, systematic, transparent. Diabetes Care.

Ettehad, D., et al. (2016). Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis. The Lancet, 387(10022), 957–967.

Hiremath, J., Kirpalani, A., Chafekar, D., & Jayagopal, P. B. (2026). Hypertension management beyond blood pressure control in India: An expert consensus on angiotensin II receptor blocker and calcium channel blocker. Cureus.

Le, N. N., Frater, I., Lip, S., & Padmanabhan, S. (2025). Hypertension precision medicine: The promise and pitfalls of pharmacogenomics. Pharmacogenomics.

Messerli, F. H., Bangalore, S., & Bavishi, C. (2018). Angiotensin-converting enzyme inhibitors in hypertension. Journal of the American College of Cardiology, 71(13), 1474–1482.

Mills, K. T., et al. (2020). Global disparities of hypertension prevalence and control. Circulation, 141(9), 777–793.

Rahman, A. R. A., Magno, J. D. A., Cai, J., Han, M., Lee, H. Y., Nair, T., Narayan, O., Panyapat, J., Van Minh, H., & Khurana, R. (2024). Management of hypertension in the Asia-Pacific region: A structured review. American Journal of Cardiovascular Drugs.

Smoli?ska, S., Antolín-Amérigo, D., & Popescu, F.-D. (2023). Bradykinin metabolism and drug-induced angioedema. International Journal of Molecular Sciences.

Taddei, S., & Bortolotto, L. A. (2016). Unraveling the pivotal role of bradykinin in ACE inhibitor activity. American Journal of Cardiovascular Drugs.

Valerio, G., Di Bonito, P., Calcaterra, V., Cherubini, V., Corica, D., de Sanctis, L., Di Sessa, A., Faienza, M. F., Fornari, E., Iughetti, L., Licenziati, M. R., Manco, M., del Giudice, E. M., Morandi, A., Salerno, M., Street, M. E., Umano, G. R., Wa?niewska, M., & Di Bonito, P. (2024). Cardiometabolic risk in children and adolescents with obesity: A position paper of the Italian Society for Pediatric Endocrinology and Diabetology. Italian Journal of Pediatrics.

Wei, Q. (2024). Study on drug optimization for patients with comorbid hypertension and coronary heart disease. Journal of Food and Drug Safety Research.

Williams, B., et al. (2018). 2018 ESC/ESH guidelines for the management of arterial hypertension. European Heart Journal, 39(33), 3021–3104.

Xie, X., et al. (2020). Comparative effectiveness of renin–angiotensin system inhibitors. BMJ, 368, m193.